A clinical trial of a new Ebola vaccine (ChAd3-EBO-Z) that resulted from an unprecedented global consortium assembled at the behest of the World Health Organization has found that it is well tolerated and stimulates strong immune responses in adults in Mali, West Africa and in the US, according to a study published today in the journal Lancet Infectious Disease. If the vaccine is ultimately found to be safe and effective, it could offer crucial protection for contacts (family members, neighbors, etc.) of patients with confirmed Ebola disease in future epidemics, thereby helping to interrupt transmission. Larger trials of the vaccine sponsored, by GSK Biologicals, have already begun.
The study, carried out in Mali, West Africa and Baltimore, included the first testing of this vaccine in adult health care workers and other at-risk persons in Africa. It identified the dose to be used in subsequent clinical trials and for large-scale manufacture of the vaccine. The researchers say that if larger trials (some already ongoing at CVD-Mali) corroborate the vaccine’s clinical acceptability and immunogenicity, and with evidence of protection from future field trials or from non-human primate challenge models, the vaccine could obtain regulatory approvals to become a tool to interrupt transmission in future outbreaks. This would be achieved by vaccinating all people who have come into contact with confirmed Ebola cases.
The investigators also found that the administration of a booster vaccination with another vector vaccine producing Ebola virus antigens led to further enhanced immune responses likely to be associated with long-lived protection. This “prime-boost” approach provides a way to vaccinate health care workers and other front-line workers who live in areas where Ebola poses a threat to re-emerge and who need prior enduring protection.
The trial was carried out by a group of faculty researchers within the Center for Vaccine Development (CVD) of the University of Maryland School of Medicine (UM SOM), led by Milagritos D. Tapia, MD and Kirsten Lyke, MD, collaborating closely with Professor Samba O. Sow, MD, MSc, Director General of the Center for Vaccine Development of Mali (CVD-Mali, an institution jointly maintained by the Ministry of Health of Mali and CVD-UM SOM).
Drs. Tapia and Lyke are also Associate Professors in the Department of Pediatrics and Medicine, respectively, at CVD-UM SOM., provided overall coordination of this study that evaluated the experimental Ebola vaccine (ChAd3-EBO-Z) developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and GlaxoSmithKline (GSK). Other key partners in the study included the University of Oxford’s Jenner Institute and the World Health Organization.
The study was the result of a consortium of the World Health Organization (WHO), the VRC, the Jenner Institute at the University of Oxford, CVD-Mali, CVD-UM SOM, and GSK Biologicals (manufacturer of the vaccine).
The study also involved others at CVD-UM SOM, including Marcelo B. Sztein, MD, and, James D. Campbell, MD, MS, both of whom are Professors of Pediatrics at UM SOM, as well as Rezwanul Wahid, PhD, Assistant Professor of Pediatrics at UM SOM.
“This is a crucial step on the road to using this vaccine in humans,” said Dr. Levine. “This gives us essential information that the vaccine is not only well-tolerated but the high dose stimulates strong immune responses in adults in West Africa, the global region where the Ebola outbreak was rampant last year.”
The Latest on: Ebola vaccine
via Google News
The Latest on: Ebola vaccine
- Our view: Vaccine campaign needed amid coronavirus pandemicon May 12, 2020 at 3:45 pm
Vaccine development often takes years, but according to the Mayo Clinic, "researchers aren't starting from scratch to develop a COVID-19 vaccine. Past research on SARS and MERS vaccines has identified ...
- CEPI Backs Novavax’s COVID-19 Vaccine Candidate with $384 Millionon May 12, 2020 at 2:02 pm
Maryland-based Novavax snagged $384 in additional grant funding to advance the company's vaccine candidate against COVID-19.
- Canadians to help develop, test potential COVID-19 vaccine by Chinese companyon May 12, 2020 at 10:51 am
For the most up-to-date COVID-19 information from the Canadian government please visit Canada.ca/COVID19 The National Research Council of Canada said Tuesday it will work with a Chinese company to try ...
- The National Research Council of Canada and CanSino Biologics Inc. announce collaboration to advance vaccine against COVID-19on May 12, 2020 at 4:47 am
One of only a handful of vaccine candidates currently in human clinical trials in the world to begin initial evaluation in CanadaMONTRÉAL, May ...
- First Thing: Is the US holding up the search for a coronavirus vaccine?on May 12, 2020 at 3:18 am
Good morning, Scientists are confident that, with a worldwide push, at least one Covid-19 vaccine can be developed and distributed in record time. And, as with the recent multinational efforts to ...
- Whitefish graduate part of vaccine researchon May 12, 2020 at 1:00 am
Myndi Holbrook is among the scientists working on the front lines for research regarding COVID-19 and those seeking a vaccine for the virus.
- Why Human Challenge Trials Will Be Necessary to Get a Coronavirus Vaccineon May 11, 2020 at 3:10 pm
"Is the risk to volunteers too high? Firefighters and physicians take on risk for the social good, as do kidney donors. Over a thousand people have already volunteered to be considered for a challenge ...
- Top scientist who battled COVID-19 says 'we will never ... live normally' without vaccineon May 11, 2020 at 1:44 pm
A top scientist who fell ill with COVID-19 says the world will never return to normal unless there is a coronavirus vaccine.
- Ebola Vaccine Market Research – Industry Analysis, Growth, Size, Share, Trends, Forecast to 2026on May 6, 2020 at 1:21 pm
May 06, 2020 (AB Digital via COMTEX) -- Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the ...
- New universal Ebola vaccine may fight all four virus species that infect humanson April 19, 2020 at 3:56 pm
New universal Ebola vaccine may fight all four virus species that infect humans Early preclinical tests in lab models are encouraging Date: April 16, 2020 Source: Cincinnati Children's Hospital ...
via Bing News